Every letter we have printed

Signalling downstream of this receptor branches, and a compound can favour one branch. Where a paper reports a single potency it has reported one branch and left the reader to assume the others follow.

I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.

Multi-receptor compounds are described as though adding a target necessarily adds effect. The published ratios differ enormously between molecules, and a compound with a weak second activity is closer to a single-target agent than the label suggests.

Nothing in receptor pharmacology predicts who will respond, and the between-individual spread in the trials is wide. Until there is a marker that identifies a responder in advance, the pharmacology explains the average and is silent about the person.

The badges that do resolve to a third-party page are a genuine improvement and deserve saying so. I have followed several from companies in your dossier programme and reached a report with a number, a date and a lot on it, which is precisely what the mechanism is for.

I collect these images. Of the thirty-one on my desk, eleven link to a report, six link to a page of reports where finding the right one is guesswork, and fourteen link to nothing at all. The proportion that survive a single click is the number worth publishing.

Community-funded testing has solved the money problem in a handful of cases, and it introduces a new one: the group choosing the target has its own preferences about the answer. It is a better arrangement than seller-funded testing and it is not neutral.

Our practice for anything contentious is to send two tubes to two laboratories on the same day from the same aliquot. It does not establish custody and it does establish whether the disagreement is about the material or about the method.

Comparing across programmes is impossible at present because none of them describes its purchasing protocol in enough detail to reproduce. Publishing the protocol matters more than publishing another result.

The number worth asking for is resolving power at the mass you care about, not the headline figure from the brochure. Instruments are specified at a mass convenient to the manufacturer, and a peptide at four thousand daltons is not that mass. Ask where the specification was measured.

For readers who want a rule of thumb: if the report does not state a resolving power, assume it was sufficient to see the molecule and insufficient to see anything close to it. That assumption has been right every time I have been able to check it.

Reasons given publicly are shaped by what the audience will accept, and cost in particular is under-reported for that reason. A private survey and a public forum will not agree, and the gap between them is itself a finding.

Social reasons are entirely absent from every list I have seen. A change in household circumstances, a partner’s view, a change of job — these end arrangements regularly and appear in no taxonomy anywhere.

Appetite returning is the mechanism and it is worth saying so directly, because the alternative explanations readers reach for are usually about willpower. Removing an appetite intervention returns appetite; that is what the intervention was doing.

Site choice affects absorption and the effect size is published for several compounds in adjacent classes. It is one of the few variables in this discussion with a measured magnitude rather than an asserted one.

The published work on this comes from long-established clinical practice in other therapeutic areas and transfers reasonably well. Citing the source would raise the standard of the discussion considerably.

Your worked example is correct and I would extend it. A 5 mg vial reconstituted with 2 mL gives 2.5 mg per mL, so 0.2 mL contains 0.5 mg and reads as 20 units on a hundred-unit barrel. Every step of that is division and every step of it gets skipped.

The date I want is not the date the document was issued but the date the injection was made. They can differ by months, and a certificate issued today from a determination performed last year describes a material that has since sat in a warehouse through a summer.

The batch number on the vial matching the batch number on the certificate is the single check I ask new staff to perform, and it takes four seconds. It is not sufficient and it is astonishingly informative, because the documents that fail it fail it obviously.

Time course is the missing dimension in most reporting. An effect present for four days and an effect present for four months appear as the same entry in an incidence table, and they are not remotely the same thing.

A short observation on reporting. Percentages without denominators are common in secondary coverage of this literature, and a rate quoted from a study arm of forty people is being read as though it came from four thousand.

Adaptation over weeks is the feature that most needs explaining and the one with the least mechanistic work behind it. Everything published addresses the acute effect, which is the part that resolves on its own.

Community-generated management advice is frequently sensible and occasionally not, and no mechanism exists to distinguish them. A publication cannot fix that and it can at least describe how the advice is generated, which is more useful than repeating it.

Mechanistic explanation is doing rhetorical work in this area that the evidence does not support. A plausible pathway makes an effect feel established, and several of the pathways in general circulation are supported by preclinical work alone.

Whatever pattern somebody follows, recording it makes the difference between an experience and a record. The absence of documented individual patterns is the reason nothing can be learned from a very large amount of use.

Extending the interval between doses is a dose reduction expressed in time rather than in milligrams. Framing it that way makes it easier to reason about and connects it to the maintenance literature rather than leaving it as a separate practice.

Measurement frequency determines how a plateau appears. Weighed weekly, a slow change is visible; weighed monthly, it looks flat. The observation interval is part of the finding and is never quoted with it.

A plateau is defined differently in every paper I have read and not defined at all in most general coverage. Before arguing about whether one occurs, somebody needs to say over what interval and by what margin.

The chain has a step nobody discusses: the person who selected the sample. If the seller chose which vial went to the laboratory, the result describes that vial and a selection decision, and the second half of that sentence never appears on the page.

Quantity tested against quantity released deserves a line. A determination on a hundred milligrams drawn from a five-kilogram campaign is a different kind of evidence from a determination on a vial drawn from a hundred-vial fill, and the certificate reports both in the same font.

Specifications that are set after the result is known are not specifications, they are descriptions. The tell is a limit that sits a fraction below the reported value on every lot. Where a company publishes one limit and holds it across a catalogue, it is telling you the number was decided in advance.

Publishing the report number is a small accountability mechanism that already works. A number that can be quoted back to the issuing laboratory turns an image into something checkable, and the laboratories I have written to have all confirmed or denied within a week.

Deamidation adds one dalton, and on the instruments most of this market uses it is invisible. It is also the degradation route that matters most for several of these sequences in storage. The measurement that would detect it is exactly the measurement nobody buys.

Aspartate isomerisation changes nothing about the mass at all. Nor does racemisation of a single residue. Both alter the molecule in ways that a chromatographic method developed for the purpose can sometimes resolve, and that a mass measurement cannot see under any circumstances.

Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.

Two services, two visual languages, no common meaning. A shield from one and a roundel from the other represent different underlying work, and the reader who has learned to recognise both has learned nothing about how they differ.

An image is a poor container for a conditional statement. Everything interesting about a determination is conditional — on the sample, the method, the date — and none of it survives compression into a graphic. The format has selected the message.

Vitamin D and calcium status are collected in some of these protocols and reported in almost none, despite being obvious effect modifiers. Where the data exists, publishing it would cost nothing.

Areal density is confounded by body size, which is precisely what is changing. That is a real limitation of the standard measurement in exactly this population, and the volumetric alternatives are not widely available.

What I would most like to see is a piece on what has not been measured. Duration beyond the trial periods, composition after regain, and the effect of a second loss cycle are all open, and the absence of data is itself worth reporting.